Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase. The company will engage in a fireside chat on August 14, 2024, at 9:30 a.m. ET.
Investors and interested parties can access a webcast of the presentation through the Investors section of Voyager's website at ir.voyagertherapeutics.com. For those unable to attend live, a replay of the webcast will be available on the company's website for a minimum of 30 days following the event.
Voyager Therapeutics (Nasdaq: VYGR), una società biotecnologica focalizzata su medicinali neurogenetici, ha annunciato la sua partecipazione alla 44ª Conferenza Annuale sul Crescita di Canaccord Genuity e Showcase delle Aziende Private. L'azienda parteciperà a un fireside chat il 14 agosto 2024, alle 9:30 ET.
Investitori e parti interessate possono accedere a un webcast della presentazione tramite la sezione Investitori del sito web di Voyager all'indirizzo ir.voyagertherapeutics.com. Per coloro che non possono assistere dal vivo, una registrazione del webcast sarà disponibile sul sito dell'azienda per un minimo di 30 giorni dopo l'evento.
Voyager Therapeutics (Nasdaq: VYGR), una empresa biotecnológica centrada en medicamentos neurogenéticos, ha anunciado su participación en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity y Showcase de Empresas Privadas. La compañía participará en un fireside chat el 14 de agosto de 2024, a las 9:30 a.m. ET.
Los inversores y las partes interesadas pueden acceder a un webcast de la presentación a través de la sección de Inversores del sitio web de Voyager en ir.voyagertherapeutics.com. Para aquellos que no pueden asistir en vivo, una repetición del webcast estará disponible en el sitio web de la empresa por un mínimo de 30 días después del evento.
Voyager Therapeutics (Nasdaq: VYGR), 신경유전 의약품에 집중하는 생명공학 회사가 Canaccord Genuity 제44회 연례 성장 회의 및 개인 회사 쇼케이스에 참가한다고 발표했습니다. 이 회사는 2024년 8월 14일 오전 9시 30분 ET에 파이어사이드 챗에 참여할 예정입니다.
투자자와 이해관계자는 Voyager 웹사이트의 투자자 섹션에서 발표의 웨비나에 접속할 수 있습니다: ir.voyagertherapeutics.com. 실시간 참석이 불가능한 분들을 위해 웨비나 재생이 이벤트 이후 최소 30일 동안 회사 웹사이트에 제공될 예정입니다.
Voyager Therapeutics (Nasdaq: VYGR), une entreprise biotechnologique axée sur les médicaments neurogénétiques, a annoncé sa participation à la 44ème Conférence Annuelle de Croissance & Showcase des Entreprises Privées de Canaccord Genuity. L'entreprise participera à un fireside chat le 14 août 2024 à 9h30 ET.
Les investisseurs et les parties intéressées peuvent accéder à un webcast de la présentation via la section Investisseurs du site web de Voyager à l'adresse ir.voyagertherapeutics.com. Pour ceux qui ne peuvent pas assister en direct, une rediffusion du webcast sera disponible sur le site de l'entreprise pendant un minimum de 30 jours après l'événement.
Voyager Therapeutics (Nasdaq: VYGR), ein Biotechnologieunternehmen, das sich auf neurogenetische Medikamente spezialisiert hat, hat seine Teilnahme an der 44. jährlichen Wachstums-Konferenz & Private Company Showcase von Canaccord Genuity angekündigt. Das Unternehmen wird am 14. August 2024 um 9:30 Uhr ET an einem Fireside Chat teilnehmen.
Investoren und Interessierte können über den Investorenbereich der Website von Voyager auf ein Webcast der Präsentation zugreifen unter ir.voyagertherapeutics.com. Für diejenigen, die nicht live teilnehmen können, wird eine Wiederholung des Webcasts für mindestens 30 Tage nach der Veranstaltung auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase on August 14, 2024, at 9:30 a.m. ET.
A webcast of the presentation may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com. A replay of the webcast will be archived on the Company's website for at least 30 days.
About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com.
Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.
Contacts
Trista Morrison, NACD.DC, tmorrison@vygr.com
Investors: Adam Bero, Ph.D., abero@kendallir.com
Media: Brooke Shenkin, brooke@scientpr.com
FAQ
When is Voyager Therapeutics (VYGR) presenting at the Canaccord Genuity Conference?
How can I watch Voyager Therapeutics' (VYGR) presentation at the Canaccord Genuity Conference?
How long will the replay of Voyager Therapeutics' (VYGR) Canaccord Genuity Conference presentation be available?
What is the focus of Voyager Therapeutics (VYGR) as a biotechnology company?
